

Audit Review Table					
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, Sub ID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2022; Date & Timestamp - 6/2/2023 3:06:39 PM					
This submission is on the stage: Submission Finalized					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (Total)		72.26%	R	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (Total)		61.56%	R	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (Total)		59.61%	R	R	Reported
Childhood Immunization Status (CIS)					
Childhood Immunization Status - DTaP		75.67%	R	R	Reported
Childhood Immunization Status - IPV		85.64%	R	R	Reported
Childhood Immunization Status - MMR		86.13%	R	R	Reported
Childhood Immunization Status - Hib		85.16%	R	R	Reported
Childhood Immunization Status - Hepatitis B		84.91%	R	R	Reported
Childhood Immunization Status - VZV		84.67%	R	R	Reported
Childhood Immunization Status - Pneumococcal Conjugate		74.45%	R	R	Reported
Childhood Immunization Status - Hepatitis A		83.94%	R	R	Reported
Childhood Immunization Status - Rotavirus		71.53%	R	R	Reported
Childhood Immunization Status - Influenza		44.77%	R	R	Reported
Childhood Immunization Status - Combo 3		70.80%	R	R	Reported
Childhood Immunization Status - Combo 7		62.77%	R	R	Reported
Childhood Immunization Status - Combo 10		35.77%	R	R	Reported
Immunizations for Adolescents (IMA)					
Immunizations for Adolescents - Meningococcal		81.27%	R	R	Reported
Immunizations for Adolescents - Tdap		82.73%	R	R	Reported
Immunizations for Adolescents - HPV		35.04%	R	R	Reported
Immunizations for Adolescents - Combination 1		80.54%	R	R	Reported
Immunizations for Adolescents - Combination 2		34.55%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		39.07%	R	R	Reported
Breast Cancer Screening (BCS)					
Breast Cancer Screening		43.09%	R	R	Reported
Cervical Cancer Screening (CCS)					
Cervical Cancer Screening		45.74%	R	R	Reported
Colorectal Cancer Screening (COL)					
Colorectal Cancer Screening (Total)		30.27%	R	R	Reported
Chlamydia Screening in Women (CHL)					
Chlamydia Screening in Women (Total)		48.30%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)					
Appropriate Testing for Pharyngitis (Total)	Y	73.55%	R	R	Reported
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)					
Use of Spirometry Testing in the Assessment and Diagnosis of COPD		20.61%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)					
Pharmacotherapy Management of COPD Exacerbation - Systemic Corticosteroid	Y	44.95%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation - Bronchodilator		51.01%	R	R	Reported
Asthma Medication Ratio (AMR)					
Asthma Medication Ratio (Total)	Y	80.60%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		52.80%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)					
Persistence of Beta-Blocker Treatment After a Heart Attack	Y	68.38%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)					
Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (Total)	Y	59.93%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (Total)		65.03%	R	R	Reported
Cardiac Rehabilitation (CRE)					
Cardiac Rehabilitation - Initiation (Total)		4.08%	R	R	Reported
Cardiac Rehabilitation - Engagement1 (Total)		3.43%	R	R	Reported
Cardiac Rehabilitation - Engagement2 (Total)		3.43%	R	R	Reported
Cardiac Rehabilitation - Achievement (Total)		1.50%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes (HBD)					

Hemoglobin A1c Control for Patients With Diabetes - HbA1c Control (<8%)		39.66%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes - Poor HbA1c Control		53.28%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		47.69%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		42.34%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
Kidney Health Evaluation for Patients With Diabetes (Total)		29.58%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Statin Therapy for Patients With Diabetes - Received Statin Therapy		47.52%	R	R	Reported
Statin Therapy for Patients With Diabetes - Statin Adherence 80%		62.12%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
Diagnosed Mental Health Disorders (Total)		28.28%	R	R	Reported
Antidepressant Medication Management (AMM)	Y				
Antidepressant Medication Management - Effective Acute Phase Treatment		59.38%	R	R	Reported
Antidepressant Medication Management - Effective Continuation Phase Treatment		40.83%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y				
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase		46.63%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase		56.63%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
Follow-Up After Hospitalization For Mental Illness - 30 days (Total)		54.61%	R	R	Reported
Follow-Up After Hospitalization For Mental Illness - 7 days (Total)		32.70%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
Follow-Up After Emergency Department Visit for Mental Illness - 30 days (Total)		56.06%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness - 7 days (Total)		40.80%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Diagnosed Substance Use Disorders - Alcohol (Total)		4.38%	R	R	Reported
Diagnosed Substance Use Disorders - Opioid (Total)		3.87%	R	R	Reported
Diagnosed Substance Use Disorders - Other (Total)		4.76%	R	R	Reported
Diagnosed Substance Use Disorders - Any (Total)		9.84%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUJ)	Y				
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (Total)		39.23%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (Total)		21.03%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
Follow-Up After Emergency Department Visit for Substance Use - 30 days (Total)		39.43%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use - 7 days (Total)		26.51%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
Pharmacotherapy for Opioid Use Disorder (Total)		15.10%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		78.21%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia			NR	NR	Not Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia			NR	NR	Not Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		52.33%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Y				
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (Total)		57.02%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)		34.76%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)		33.45%	R	R	Reported
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)					

<i>Non-Recommended Cervical Cancer Screening in Adolescent Females</i>		0.49%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
<i>Appropriate Treatment for Upper Respiratory Infection (Total)</i>		81.64%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
<i>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total)</i>		53.61%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
<i>Use of Imaging Studies for Low Back Pain (Total)</i>		72.48%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
<i>Use of Opioids at High Dosage</i>		4.21%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
<i>Use of Opioids From Multiple Providers - Multiple Prescribers</i>		14.82%	R	R	Reported
<i>Use of Opioids From Multiple Providers - Multiple Pharmacies</i>		1.54%	R	R	Reported
<i>Use of Opioids From Multiple Providers - Multiple Prescribers and Multiple Pharmacies</i>		0.97%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
<i>Risk of Continued Opioid Use - >=15 Days (Total)</i>		4.96%	R	R	Reported
<i>Risk of Continued Opioid Use - >=31 Days (Total)</i>		3.47%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
<i>Adults' Access to Preventive/Ambulatory Health Services (Total)</i>		72.78%	R	R	Reported
Annual Dental Visit (ADV)	Y				
<i>Annual Dental Visit (Total)</i>		49.57%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
<i>Initiation and Engagement of Substance Use Disorder Treatment - Initiation of SUD Treatment - Total (Total)</i>		45.97%	R	R	Reported
<i>Initiation and Engagement of Substance Use Disorder Treatment - Engagement of SUD Treatment - Total (Total)</i>		15.97%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
<i>Prenatal and Postpartum Care - Timeliness of Prenatal Care</i>		82.97%	R	R	Reported
<i>Prenatal and Postpartum Care - Postpartum Care</i>		70.80%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
<i>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total)</i>		62.17%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
<i>Well-Child Visits in the First 30 Months of Life (First 15 Months)</i>		61.70%	R	R	Reported
<i>Well-Child Visits in the First 30 Months of Life (15 Months-30 Months)</i>		64.24%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
<i>Child and Adolescent Well-Care Visits (Total)</i>		43.48%	R	R	Reported
Frequency of Selected Procedures (FSP)			R	R	Reported
Ambulatory Care (AMB)			R	R	Reported
Inpatient Utilization - General Hospital/Acute Care (IPU)			R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
<i>Antibiotic Utilization for Respiratory Conditions (Total)</i>		23.33%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			NR	NR	Not Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
<i>Childhood Immunization Status - DTaP</i>		68.37%	R	R	Reported
<i>Childhood Immunization Status - IPV</i>		83.77%	R	R	Reported
<i>Childhood Immunization Status - MMR</i>		84.30%	R	R	Reported
<i>Childhood Immunization Status - Hib</i>		83.01%	R	R	Reported
<i>Childhood Immunization Status - Hepatitis B</i>		83.95%	R	R	Reported
<i>Childhood Immunization Status - VZV</i>		83.55%	R	R	Reported
<i>Childhood Immunization Status - Pneumococcal Conjugate</i>		70.77%	R	R	Reported
<i>Childhood Immunization Status - Hepatitis A</i>		83.42%	R	R	Reported
<i>Childhood Immunization Status - Rotavirus</i>		69.44%	R	R	Reported
<i>Childhood Immunization Status - Influenza</i>		41.68%	R	R	Reported
<i>Childhood Immunization Status - Combo 3</i>		61.12%	R	R	Reported
<i>Childhood Immunization Status - Combo 7</i>		54.48%	R	R	Reported
<i>Childhood Immunization Status - Combo 10</i>		31.37%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
<i>Immunizations for Adolescents - Meningococcal</i>		80.89%	R	R	Reported
<i>Immunizations for Adolescents - Tdap</i>		82.43%	R	R	Reported
<i>Immunizations for Adolescents - HPV</i>		32.69%	R	R	Reported

<i>Immunizations for Adolescents - Combination 1</i>		80.20%	R	R	Reported
<i>Immunizations for Adolescents - Combination 2</i>		31.96%	R	R	Reported
Breast Cancer Screening (BCS-E)					
<i>Breast Cancer Screening</i>		42.96%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
<i>Colorectal Cancer Screening (Total)</i>			NR	NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)					
<i>Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase</i>			NR	NR	Not Reported
<i>Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase</i>			NR	NR	Not Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)					
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (Total)</i>			NR	NR	Not Reported
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)</i>			NR	NR	Not Reported
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)</i>			NR	NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
<i>Depression Screening and Follow-Up for Adolescents and Adults - Depression Screening (Total)</i>			NR	NR	Not Reported
<i>Depression Screening and Follow-Up for Adolescents and Adults - Follow-Up on Positive Screen (Total)</i>			NR	NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
<i>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Total (Total)</i>			NR	NR	Not Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
<i>Depression Remission or Response for Adolescents and Adults - Follow-Up PHQ-9 (Total)</i>			NR	NR	Not Reported
<i>Depression Remission or Response for Adolescents and Adults - Depression Remission (Total)</i>			NR	NR	Not Reported
<i>Depression Remission or Response for Adolescents and Adults - Depression Response (Total)</i>			NR	NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
<i>Unhealthy Alcohol Use Screening and Follow-Up - Unhealthy Alcohol Use Screening (Total)</i>			NR	NR	Not Reported
<i>Unhealthy Alcohol Use Screening and Follow-Up - Alcohol Counseling or Other Follow-Up Care (Total)</i>			NR	NR	Not Reported
Adult Immunization Status (AIS-E)					
<i>Adult Immunization Status - Influenza (19-65)</i>		17.60%	R	R	Reported
<i>Adult Immunization Status - Td/Tdap (19-65)</i>		33.13%	R	R	Reported
<i>Adult Immunization Status - Zoster (50-65)</i>		9.81%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
<i>Prenatal Immunization Status - Influenza</i>		30.60%	R	R	Reported
<i>Prenatal Immunization Status - Tdap</i>		58.55%	R	R	Reported
<i>Prenatal Immunization Status - Combination</i>		24.67%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
<i>Prenatal Depression Screening and Follow-Up - Depression Screening</i>		0.00%	R	R	Reported
<i>Prenatal Depression Screening and Follow-Up - Follow-Up on Positive Screen</i>			NA	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
<i>Postpartum Depression Screening and Follow-Up - Depression Screening</i>		0.00%	R	R	Reported
<i>Postpartum Depression Screening and Follow-Up - Follow-Up on Positive Screen</i>			NA	R	Reported